Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 3/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 6/20 | 0.38 |
| ▸ | SCN2A | Q99250 | 5/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CTSA | P10619 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | GRN | P28799 | 1/20 | 0.35 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2935254 | 0.89 | CNR2 (0.52) | CNR2CNR1PSMB5CTSA | |
| SCHEMBL2929287 | 0.86 | NPC1 (0.48) | CNR2CNR1PSMB5SCN10ASCN2A | |
| SCHEMBL2927821 | 0.84 | KMO (0.38) | CNR2CNR1PSMB5LMNAPOLB | |
| SCHEMBL2930530 | 0.84 | GRN (0.52) | CNR1PSMB5NPC1RAB9AGRN | |
| SCHEMBL2935262 | 0.84 | EGLN1 (0.46) | CNR1PSMB5LMNAPOLBCTSA | |
| SCHEMBL2930927 | 0.84 | HDAC1 (0.47) | SCN10ASCN2AKDM4EALDH1A1CTSA | |
| SCHEMBL13079104 | 0.83 | PSMB5 (0.59) | PSMB5CTSA | |
| SCHEMBL2935509 | 0.83 | SMN1; SMN2 (0.46) | PSMB5POLBCTSANPC1RAB9A | |
| SCHEMBL2930833 | 0.82 | SMN1; SMN2 (0.47) | LMNAPOLBKDM4EALDH1A1NPC1 | |
| SCHEMBL2927696 | 0.82 | CTSA (0.44) | PSMB5LMNAPOLBKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1846424-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-01-27 | — | — | EP | claimed |
| US-7468383-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2008-12-23 | — | — | US | claimed |
| US-20060189806-A1 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2006-08-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189806-A1 | Proteasome inhibitors and methods of using the same | PSMB11, PSMB5, PSMB6 | CNR2 4830/4885CNR1 4721/4885PSMB5 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.